Detalhe da pesquisa
1.
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator.
Drug Metab Dispos
; 49(5): 389-394, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632715
2.
The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant.
Pulm Pharmacol Ther
; 68: 102030, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826946
3.
Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.
Pulm Pharmacol Ther
; 72: 102097, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800680
4.
Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
AAPS J
; 25(1): 25, 2023 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788163
5.
Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.
Bioorg Med Chem Lett
; 22(12): 4028-32, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22579486
6.
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
J Med Chem
; 64(11): 7241-7260, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028270
7.
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Clin Drug Investig
; 37(5): 465-472, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28155129
8.
Population Pharmacokinetic Analysis of Fevipiprant in Healthy Subjects and Asthma Patients using a Tukey's g-and-h Distribution.
Drug Res (Stuttg)
; 71(6): 326-334, 2021 Jul.
Artigo
em Alemão
| MEDLINE | ID: mdl-33682912
9.
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 74(4): 867-74, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25193431
10.
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Clin Cancer Res
; 17(5): 989-1000, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21245089